Christopher Mitton

MDNA Life Sciences, Inc. engages in the development of molecular tests based on the mitochondrial genome. It focuses on the development and commercial application of mitochondrial DNA based biomarkers for the early detection of prostate, ovarian and lung cancers, and endometriosis. The company was founded by Mark Birch-Machin, Robert Thayer, and Ryan L. Parr in 2001 and is headquartered in West Palm Beach, FL.

Cancer Genetics, Inc. engages in the development, commercialization, and sale of molecular and biomarker-based tests and services. Through its Select One Clinical Trials program, the firm provides a range of clinical trial services for both oncology and non-oncology genetic testing such as bioinformatics, biomarker solutions, bio repository solutions, consulting, cytogenetic testing, nucleic acid extraction and purification, flow cytometry, Focus: NGS Panel, gene expression analyses, genotyping, and pharmacogenomics. The company was founded by Raju S. K. Chaganti on April 8, 1999 and is headquartered in Rutherford, NJ.